latest news releases from the newsroom
XOMA and Takeda Expand Collaboration for Therapeutic Antibody Discovery and Development
BERKELEY, Calif. and OSAKA, Japan, Feb. 28, 2007 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) and Takeda Pharmaceutical Company Limited (TSE4502:Takeda) announced today they have amended their existing agreement to increase the number of potential therapeutic antibody programs under the collaboration initiated in November of 2006. With this expansion, XOMA estimates the aggregate upfront, R&D funding, milestone and other payments could exceed $230 million before royalties over the life of the agreement. Since entering the original agreement four months ago, XOMA has received or is otherwise due approximately $8 million as various collaboration-related payments.
XOMA Announces Expiration of Oncology Exclusivity Obligation With Novartis
BERKELEY, Calif., Feb. 28, 2007 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) announced today that pursuant to the terms of its collaboration agreement with Chiron Corp. (subsequently acquired by Novartis AG, "Novartis"), the parties' mutual obligations to conduct antibody discovery, development and commercialization work together on an exclusive basis in oncology have expired, except with respect to existing collaboration projects which have reached the development stage. XOMA and Novartis are continuing to jointly develop multiple products, including HCD122, an anti-CD40 fully-human monoclonal antibody possessing a unique dual mechanism of action that is currently in two Phase I clinical trials for Multiple Myeloma and Chronic Lymphocytic Leukemia.